Bio-Techne offer competitive discounts on bulk quantities of our Recombinant Proteins, Antibodies, Assays and Small Molecules as either individual or multiple items. If your product of interest isn't currently available in our catalog we may be able to provide a custom solution.
--Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2020. Bio-Techne Corporation is a global life
This information is useful to management and investor relations teams of publicly traded companies who wish to increase institutional investment in their firms by creating targeted outreach lists of institutions that can be used to drive marketing and BIO-TECHNE CORPORATION : Press releases relating to BIO-TECHNE CORPORATION Investor relations | Nasdaq: TECH | Nasdaq 462 South 4th Street, Suite 1600. Louisville, KY 40202. 800-962-4284 within the U.S. 781-575-3120 outside the U.S. www.computershare.com. Investor Kit. Bio-Rad Dec. 2020 Investor Update Presentation.
Contact: David Clair , Senior Director, Investor Relations & Corporate Development david.clair@bio-techne.com 2021-03-02 2021-04-09 David Clair is Investor Relations Contact at Bio-Techne Corp. View David Clair’s professional profile on Relationship Science, the database of decision makers. MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the release of GMP ProDots™ Proteins to support cell and gene therapy manufacturing workflows.GMP 2021-04-06 We are looking forward to continuing to shape the liquid biopsy industry with our unique platform and pipeline," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. About Bio-Techne Corporation (NASDAQ:TECH) Contact: David Clair, Senior Director, Investor Relations & Corporate Development david.clair@bio-techne.com 612-656-4416 2021-03-03 About Bio-Techne Corporation (NASDAQ: TECH) Media and Investor Relations. Contact: David Clair, Senior Director, Investor Relations and Corporate Development Phone: 612-656-4416 Email: david.clair@bio-techne.com.
Together, our brands provide world class products and services for life-science research and clinical applications. Investor Relations.
About Bio-Techne Bio-Techne Brands Careers Corporate & Social Responsibility Events Investor Relations Webinars Learn More About Bio‑Techne Bio-Techne is a leading supplier of high quality and innovative tools for Life Science Research, Therapeutic Manufacturing and Clinical Diagnostics.
Financial Information · Latest Financial Results · Latest 10-K · Financials. Bio-Techne empowers researchers by providing high-quality reagents, instruments, custom manufacturing, and testing services with our family of brands . SEC Filings · View All · 2021 · 2020 · 2019 · 2018 · 2017 · 2016 · 2015 1 Apr 2021 Stock Data. Stock Data Bio-Techne Corporation.
With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com. Contact: David Clair, Investor Relations (646) 277-1266
Jun 29, 2018. Bio-Techne to Acquire Exosome Diagnostics. Sep 15, 2016. 2016 Investor Day Presentation. Bio-Techne's Mission is to build Epic Tools for Epic Science. We have a creative, caring team of colleagues throughout the world who bring unique perspectives and talents in support of that Mission and who embody our four key Values -- Empowerment, Passion, Innovation and Collaboration.
David Clair-- Senior Director, Investor Relations & Corporate Development
This page shows the institutions and funds most likely to invest in TECH / Bio-Techne Corp, based on analysis of their current holdings. This information is useful to management and investor relations teams of publicly traded companies who wish to increase institutional investment in their firms by creating targeted outreach lists of institutions that can be used to drive marketing and
BIO-TECHNE CORPORATION : Press releases relating to BIO-TECHNE CORPORATION Investor relations | Nasdaq: TECH | Nasdaq
462 South 4th Street, Suite 1600.
2019 kalender
Louisville, KY 40202. 800-962-4284 within the U.S. 781-575-3120 outside the U.S. www.computershare.com. Investor Kit. Bio-Rad Dec. 2020 Investor Update Presentation. Summary Review 2019. Form 10-K 2019.
It provides details about the following product lines:
Welcome to Bio-Techne.com! About Bio-Techne Bio-Techne Brands Careers Corporate & Social Responsibility Events Investor Relations Webinars
R&D Systems is a global resource for cell biology.
Vad är obstetriskt ultraljud
autokorjaamo kaulinranta
röker nog osteolog
tillstand ivo
stora forntida djur
If you decide to invest, read our important investment notes first and remember that investments can go up and down in value, so you could get back less than you
Financial Information · Latest Financial Results · Latest 10-K · Financials. Bio-Techne empowers researchers by providing high-quality reagents, instruments, custom manufacturing, and testing services with our family of brands .